Ebola, the Negative Stranded RNA Virus by Farman, Aqsa et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
1Chapter
Ebola, the Negative Stranded RNA 
Virus
Aqsa Farman, Syed Lal Badshah, Khalid Khan, 
Nasir Ahmad and Abdul Naeem
Abstract
Ebola virus (EBV) is a deadly virus that has resulted in a number of deaths 
during its outbreaks in Africa in 2014–2016 and 2018–2019. This virus causes a 
hemorrhagic fever like other pathogenic viruses of the Filoviridae family with 
high mortality rate. The exact reservoir of the ebola virus is not known, but dif-
ferent mammal groups are the source from which it is transferred to the human 
population. The transmission among the human population is through body fluids 
of patients and also through aersol droplets in the air. The role of different glyco-
proteins in the budding formation has helped a lot in understanding the physiology 
of the ebola virus. Most of these viral glycoproteins synthesis and the replication 
enzymes offer a good inhibitory target for drug design against the ebola virus. 
Recently, different groups have claimed the development of a successful vaccine for 
the ebola virus. However, the availability of the vaccines to the poor population of 
Africa and other parts of the world is still not practical.
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1. Introduction and background
The Ebola virus was first discovered back in 1976 when its breakout occurred 
simultaneously in South Sudan and in the area of Ebola River in Yambuku city of 
Democratic Republic of Congo (Figure 1) [1]. It reemerges in 1990s, 2000s, peaked 
in 2014 and 2018–2019 (Figure 1). This RNA viral disease caused hemorrhagic 
fever in humans and non-human primates [2]. The African originated species 
of Ebola virus fatality rate in humans is nearly 90% [2]. Ebola, Marburg, and 
Cueva virus are the three infectious viruses with a common ancestor of the family 
Filoviridae [2]. The word “filo” in Filoviridae is derived from the Latin word film, 
which means thread like, as these virions appear thread-like under the electron 
microscope [3]. The Filoviridae family is part of the order Mononegavirales, class 
Monjiviricetes and phylum Negarnaviricota in the virus taxonomic classification 
[4, 5]. Ebola, also known as Ebola virus disease (EVD/EBOV) and Ebola hemor-
rhagic fever (EHF) in the past, is a filamentous, enveloped, non-segmented, 
single stranded negative sense ribonucleic acid (RNA) virus [4]. The replication of 
Filoviridae family of viruses takes place in the cytoplasm of the host cell [6, 7]. The 
genomic RNA is non-contagious alone because it is not able to serve as a template 
for protein synthesis [6, 7]. To start the transcription of positive-sense messenger 
RNA (mRNA) the viral protein must connect with the genomic RNA [6, 7]. The 
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objective of this work is to provide firsthand information regarding the EBOV 
origin, infection, control and progress in vaccine development.
1.1 Origin
The Ebola virus is taxonomically classified into five species. These species 
includes Zaire Ebola virus (EBOV), Reston Ebola virus (RESTV), Taï Forest Ebola 
virus (TAFV) or Coted’Ivoire Ebola virus (CIEBOV) [9], Sudan Ebola virus (SUDV), 
and Bundibugyo Ebola virus (BDBV) [10]. Four of these species are responsible to 
cause disease in humans and one in nonhuman primates [10]. The species of Ebola 
viruses are named from where they originated for the first time [11]. The BDBV was 
first found in 2007 in Bundibugyo district of Uganda with 116 cases and fatality rate 
of 25% [12, 13]. RESTV emerged in 1989 in Reston (Virginia), USA, causing diseases 
in nonhuman primates [14, 15]. SUDV was first discovered in 1976 in a cotton fac-
tory in South Sudan (Nzara). Its mortality rate varies from 53 to 68%. The mortality 
rate is the death rate due to certain disease in a particular population. CIEBOV (Tai 
forest virus) was first reported in 1994. The virus appeared in chimpanzees in Africa 
in Tai forest [16]. ZEBOV has the highest lethality rate up to 90%, which includes 
the first appeared virus and the most current outbreak [17].
1.2 History
The Ebola virus is named after a small river, Ebola in Zaire and this viral infec-
tion first appeared in 1976 in both South Sudan and Zaire in the African continent 
[18–20]. The international teams of WHO reached the affected area but were 
unsuccessful in saving more lives and collecting vital information due to lack of 
medical facilities and illiteracy in rural areas [21]. This virus family becomes geneti-
cally more advanced and spread into other areas, and appeared in the united states 
in 1989 [22]. EBOV did not appear in Africa for 15 years but as the natural reservoir 
Figure 1. 
Reported cases and deaths from EBOV in different countries from 1976 to 2014 according to WHO [8].
3Ebola, the Negative Stranded RNA Virus
DOI: http://dx.doi.org/10.5772/intechopen.91776
was not completely eliminated and due to this reason the virus showed itself again 
in 1994–1996 [23]. During 1994–1996, the new subtype of Ebola Coted’Ivoire was 
discovered, while the old subtypes were also present. The people infected were liv-
ing near the tropical forest area. The ethnologist’s discovered that the fifth subtype 
was found in the chimpanzee group with a high fatality rate. They were transferred 
to Switzerland for suitable facilities and medical care by a group of scientists [24]. 
The outbreak in 2014 has the highest fatality rates in the history of EBOV [25].
1.3 Transmission, symptoms, and treatment
EBOV is a rare and deadly disease caused by infection with one of the Ebola 
virus strains. Humans and non-human primates are the primary hosts of Ebola 
[26]. The different types of insectivorous bat genus, especially Mops condylurus and 
frugivorous bat species are also the host of EBOV [27–29]. The fruits eating bat is 
also a common reservoir of ebola virus [30, 31]. The virus is transmitted through 
contaminated blood and bodily fluids of infected person or animal. Fever, muscle 
ache, loss of appetite, and fatigue are the common symptoms after onset of EBOV, 
while in fatal cases, severe vomiting, diarrhea, hemorrhage, septic shock, and 
multi-organ failure may occur that may lead to death in 30–90% patients [32]. The 
patients can be treated as the symptoms of EBOV appear in them. Currently, there 
is no proper Federal Drug Authority (FDA) approved medicines or vaccines. The 
following are some of the interventions and precautions for survival against EBOV;
a. Intravenous fluids (IV) and body salts should be regularly provided to the 
EBOV infected patients.
b. The blood pressure and oxygen status of patients should be monitored and 
maintained to the normal level.
c. The blood lost during the illness should be replaced and medicines should be 
provided to control the blood loss.
d. The patient should increase the intake of fluids.
e. The other infections which develop during treatment should also be treated 
simultaneously [33].
1.4 EBOV genomic organizations
The EBOV genome has nucleotide sequences which are extragenic. The 
sequences combine to produce secondary structures that contain 3′ and 5′ ends. 
The genome serves to initiate transcription and genome replication [34, 35]. The 
negative-stranded RNA genome of EBOV contains seven important genes that are 
arranged in a linear fashion and has a total length of approximately 19 kilobases 
and it translated into eight proteins [36]. Its sequence is as follows 3′-NP, VP35, 
VP40, GP, VP30, VP24, L-5′as shown in Figure 2. The VP (35) is RNA-dependent 
RNA polymerase cofactor, VP(40) is a matrix protein, GP(1,2) is spike glycopro-
tein, VP(30) is a transcriptional activator, VP (24) is the second protein matrix 
and (L) is RNA polymerase enzyme [6]. The RNA genome of the virus is coated 
by a complex of ribonuclear protein (RNP). It is also known as nucleocapsid. The 
nucleocapsid is composed of major nucleoprotein (NP), minor nucleoproteins that 
include VP(30), VP(35), and polymerase (L) protein as shown in Figure 3 [37, 38]. 
The above complex is then enveloped in a layer of matrix. The matrix consists of 
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the major and minor matrix protein VP40, VP24, respectively. Then, the matrix 
proteins are encapsulated by a double layer of lipid which is then peppered with the 
viral glycoprotein (GP) that help in binding to the host cell [39, 40]. All five EBOV 
species discovered so far has the same GP gene organization which is divided into 
sGP, GP1, GP2, and ssGP [41, 42].
1.5 Structure of glycoproteins
It has been observed that most of the viral components play an active role in 
the pathogenesis and infection of this viral disease, but the major role is played by 
the glycoproteins of the EBOV [45]. Thus, they possess a significant importance 
in the virulence of EBOV and targeting its synthesis is one of important step for 
controlling this infection [45]. EBOV includes different glycoproteins each of 
which plays their roles in different aspects of viral life cycle. Each gene product 
has distinct biochemical and biological properties [46, 47]. The fourth gene, GP 
Figure 2. 
Important proteins in the RNA genome of EBOV [43].
Figure 3. 
The virion structure showing the nuclear material and glycoproteins [44].
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is formed by a process known as glycosylation in which carbohydrate are linked 
covalently to the polypeptide chain [48].
1.6 Production of glycoproteins
The biosynthesis of glycoproteins occurs by transcription and expression strate-
gies. The precursor of the secreted glycoproteins and full length glycoproteins are 
the initial products of EBOV glycoprotein. Pre-sGP is transcripted and translated 
to soluble products sGP and ∆-peptide while glycoprotein GP1, 2 is cleaved to GP1 
and GP2. These two fragments are linked together by disulfide-bonding (S▬S). The 
GP1 helps in binding to the host cell and has a crucial role of EBOV entry across the 
host cell membrane [49]. The flowchart is shown in Figure 4 [45].
1.7 Classification and functions of EBOV glycoproteins
The Ebola virus actually produces the following soluble glycoproteins during 
infection:
1.7.1 Small secreted glycoprotein of EBOV
Small secreted glycoprotein (ssGP) is translated from part of mRNA. It is 
nonstructural and generated when two adenosines are combined or one is deleted 
during transcription [50]. The ssGP has monomeric structure which has identi-
cal 295 amino acids from starting point with secreted GP and full length GP but 
they vary at the C-terminus of the full length glycoprotein [51]. The host ADAM17 
metalloprotease enzyme is responsible to generate ssGP. The antibodies that neu-
tralize the viral glycoproteins are quickly blocked by the secreted complex GP [14]. 
This complex plays a key function in the virus pathogenesis. In spite of extensive 
necrosis and massive virus production, it therefore contributes to less inflammatory 
reaction seen during the infection [14]. When the EBOV enters the host cell, the 
Figure 4. 
Biosynthesis of glycoproteins of EBOV [45].
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small secretary glycoprotein neutralizes the host cell neutrophils through CD16b 
and resulting in lymphocyte death and further vascular dysregulation [52].
1.7.2 Secreted or soluble glycoprotein and delta peptide of EBOV
The soluble glycoprotein (sGP) is a non-structural protein with a single frame 
and has total 364-372 residues. At the N-terminal, 295 residues which also include 
the signal sequence are similar with full length GP. It differs in the length of 
C-terminal sequences [46, 50]. The formation of sGP is from Precursor (pre-sGP). 
Unedited mRNA is frequently produced from infected cells which results in the for-
mation of precursor (pre-sGP). Precursor (pre-sGP) is cleaved by the furin protein 
to produce sGP and delta peptide [46, 50]. The orientation of sGP is antiparallel and 
linked together by disulfide bonding. It possesses dimerization between amino and 
carboxy groups as shown in Figure 5. The sGP plays a role in the evasion of humoral 
immune response by absorbing elicited antibodies. It also predicted to be involved 
in interaction with neutrophils of the host cells and their neutralization [53].
1.7.3 Envelope or full length glycoprotein of EBOV
It is generated on the surface of mature infectious virions and formed when 
RNA is edited by the process of transcription. The GP protein has 676 amino acids 
and is a structural polypeptide chain. It is encoded in two frames and functions in 
attachment and entry of virus into the defenseless cells of the host [48]. The GP 
is sub-divided into two glycoproteins; GP1 and GP2. They are membrane associ-
ated proteins and are linked with each other through disulfide bonding as shown 
in Figure 6. The GP1 is 130 kDa and GP2 is 24 kDa in size [47]. The GP1 helps in 
attachment to the receptors which are present on target cells [54]. The interactions 
allow the binding of viral particles to the dendritic cells and thus facilitates virus 
into cell entry [48]. GP2 is known as a class I viral fusion protein. Some character-
istics of GP2 subunit protein of EBOV are as follows: towards the C-termini is the 
transmembrane helix while the “fusion- peptide” is found at the N-terminus [55]. 
The formation of this structure drives to combine the cell membranes of target cells 
and EBOV. It also helps the particles to enter into the cytoplasm of a healthy cell. 
The penetration of virus is mediated by the fusion of the membranes of endosomes 
with the endocytosed virus particle [56].
Survey of the literature showed that currently there are no crystal structures of 
both secreted and envelope glycoproteins available which are important for design-
ing novel drugs that can inhibit the attachment of these glycoprotein to the host cells 
receptors and also to halt the activity of the secretary and soluble glycoproteins. In 
one of our study, we have constructed 3D structures through homology modeling 
[57]. The molecular dynamics simulation study of the obtained homology models and 
several drug docking results showed that these proteins can be targeted with small 
Figure 5. 
EBOV soluble glycoprotein (sGP) involved in host neutrophil neutralization and immune system evasion.
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ligand molecules [57]. Further computation studies and experimental work will prove 
the usefulness of these small molecules as inhibitor of the EBOV important proteins 
[57]. The current advancement in cryo-electron microscopy should be utilized for the 
elucidation of EBOV structure like that of influenza, dengue, Zika and other arboviral 
diseases [57–60]. The availability of protein structure will help in molecular dynamics 
simulation and docking of these important viral proteins with suitable ligands and it 
will enhance the exploration of novel antiviral drugs [59, 60].
1.8 Progress in vaccines development for EBOV
A number of researchers have developed vaccines in their laboratories which 
are in initial stages and have some minor side effects [61]. A recent investigation 
showed the development of a vaccine when the EBOV glycoproteins like GP and 
VP40 were injected in the guinea pigs and a protective immune response was 
observed [62]. The constructed vaccine recovers the infected rhesus macaque in a 
single dose [62]. Similarly the glycoproteins along with the matrix proteins VP24 
and VP40 and in their absence were also tested in guinea pigs [63]. The antibodies 
produced against these antigens completely cure the tested subjects from EBOV 
[63]. Several other vaccine of EBOV was developed recently and they showed 
promising results in murine models with high success rate [64]. Thus, a success in 
the development of vaccine has been achieved but passing the clinical trials and its 
availability in the market will take time.
1.8.1 Prevention and control
A number of steps can be taken for the control and prevention of EBOV break-
out and its spread. It is always better to avoid traveling to areas of EBOV outbreak 
and strict quarantine should be imposed on the people of that particular towns. 
Only medical teams with proper safety masks, cloths should be allowed for the 
care of patients infected with EBOV [65]. The damaged fruits and vegetables 
eaten by bat should not be consumed. Bats, monkeys, pangolins, and other wild 
animals’ meat and their utilization in food, medicine, and soaps should be avoided 
[66]. Contacting these animals should be discouraged. Proper washing of hands 
and use of sanitizers should be encouraged in schools, airports, shopping malls, 
trains, and all public areas. It is always necessary for hospitals and health working 
organizations to share and spread information related to viral diseases outbreak to 
the general public on time and awareness campaigns should be launched at regular 
intervals of time. The advancement in cryo-electron microscopy should be utilized 
for structural resolution of the important enzymes of the EBOV and other fatal 
viruses so that novel drugs can be synthesized for their inhibition and control [67].
Figure 6. 
EBOV envelope glycoprotein.
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2. Conclusions
With the 2018 outbreak of EBOV and high probability of future outbreaks and 
spread, it is highly important to expediate the production of effective vaccine and 
immunization of vulnerable population across different countries in Africa, that 
will help in the control of this viral disease. Joint efforts are also needed by the local 
public health departments and scientific community across the globe for informa-
tion sharing on different viral outbreaks, vaccine development, and easy access of 
immunization and medicines.
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